1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3

Thomas Enzler, Anna Nguyen, Jamal Ghazi Misleh et al. · Annals of Oncology · 2023

Cited by 3 works. doi:10.1016/j.annonc.2023.09.2574 Open-access PDF

Authors

References